our presenters include uday kumar who's the founder and chief medical officer of irhythm technology,vicki seyfert-margolis who's the senior advisor for science innovation and policy for the food and drug administration. lou garrison who's a professor in pharmaceutical outcomes research and policy in the department of pharmacy and an adjunct professor in the departments of global health and health services at the university of washington. and sean tunis who's the founder and director for the medical technology policy. so as we've done in the last panel, i'll ask people with me on stage to make a few opening comments and then we're going to turn this into a discussion about these issues related to measuring value in medical innovation. so let me start with uday. when you founded irhythm technology, uday, i know your explicit goal was to develop medical technologies that not just improved health but also saved money and the explicit goal in process to be able to measure how that was occurring. so maybe you can tell us about that experience and the implications for what we're talking abo

our presenters include uday kumar who's the founder and chief medical officer of irhythm technology,vicki seyfert-margolis who's the senior advisor for science innovation and policy for the food and drug administration. lou garrison who's a professor in pharmaceutical outcomes research and policy in the department of pharmacy and an adjunct professor in the departments of global health and health services at the university of washington. and sean tunis who's the founder and director for the medical technology policy. so as we've done in the last panel, i'll ask people with me on stage to make a few opening comments and then we're going to turn this into a discussion about these issues related to measuring value in medical innovation. so let me start with uday. when you founded irhythm technology, uday, i know your explicit goal was to develop medical technologies that not just improved health but also saved money and the explicit goal in process to be able to measure how that was occurring. so maybe you can tell us about that experience and the implications for what we're talking abo